News

The company is organizing a multi-center Phase 3 trial investigating asimadoline in D-IBS, conducted under a Special Protocol Assessment agreement with the FDA for US registration. Tioga Pharma

RBM’s protein detection platform offers pharmaceutical companies with critical information for accelerating drug development research and improve clinical trial outcomes. The company’s proprietary Multi Analyte Profiling (MAP) technology

Completion of the study enables Fero Industries to move forward with plans for registration, licensing and distribution of Sucanon across the Middle East. The pre-clinical and clinical studies

The trial which is sponsored by the National Institutes of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), expects to recruit around

The results from the trial showed an objective response rate (ORR) of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine

Yellox is a non-steroidal anti-inflammatory drug (NSAID) indicated as a treatment for postoperative ocular inflammation following cataract extraction in adults. Under an agreement signed between CROMA Pharma and

Following the acquisition, Trident will become the wholly owned subsidiary of INC Research and will be operating as Trident Clinical Research, an INC Research company, through its offices

Nextrials claims Prism can be fully integrated with platforms used for electronic health records (EHR) by the healthcare industry. By receiving a constant flow of data, Prism enables

Prior to licensing the manufacturing facility, the Spanish Medicines Agency has conducted inspection on 15 and 16 February 2011. Midatech claims its biocompatible nanoparticles possess a number of